PrimeNeuro

Presentation: Growing Neurodiversity

PrimeNeuro is commercializing technology to determine whether an infant will be on the autism spectrum as they grow up. This capability happens at 6-to-12 months of age which is far earlier than ever before and is supported by clinical evidence in peer-reviewed publications. PrimeNeuro’s technology has been validated by the National Institute of Mental Health via funding of approximately $3.5 million to date and we are actively working with collaborators now.

Presenter: Sam Tetlow, co-founder, PrimeNeuro; Brad Bower, CEO, PrimeNeuro